Mahon Caroline, Purvis Diana, Laughton Stephen, Bradbeer Peter, Teague Lochie
Department of Paediatric Dermatology, Starship Children's Health, Auckland, New Zealand.
Pediatr Dermatol. 2014 Sep-Oct;31(5):603-7. doi: 10.1111/pde.12380. Epub 2014 Jun 12.
Imatinib mesylate was the first of several tyrosine kinase inhibitors approved for use in the treatment of a number of human cancers. Adverse cutaneous reactions to imatinib are common. Pseudoporphyria has been infrequently reported in adults undergoing imatinib therapy for chronic myeloid leukemia. We present two children with pseudoporphyria induced by imatinib therapy for hematologic malignancies. In view of the burgeoning use of imatinib in children, physicians should be aware that pseudoporphyria may develop as a consequence of imatinib therapy.
甲磺酸伊马替尼是首批被批准用于治疗多种人类癌症的几种酪氨酸激酶抑制剂之一。伊马替尼引起的皮肤不良反应很常见。在接受伊马替尼治疗慢性粒细胞白血病的成人中，伪卟啉症的报告较少。我们报告了两名因伊马替尼治疗血液系统恶性肿瘤而诱发伪卟啉症的儿童。鉴于伊马替尼在儿童中的使用日益增多，医生应意识到伪卟啉症可能是伊马替尼治疗的结果。
